Showing 1391-1400 of 1747 results for "".
- New Nair Survey Shows Unwanted Body Hair is No Confidence Boosterhttps://practicaldermatology.com/news/new-nair-survey-shows-unwanted-body-hair-is-no-confidence-booster/2458552/Just shy of 80 percent of women are more confident when they do not have unwanted body hair, according to a recent online survey conducted by Harris Poll on behalf of Church & Dwight Co., Inc., the makers of Nair™. Who Wears Short Shorts? Nair for Short Shorts</
- Novel Topical AD Drug Shows Promise in Phase 2 Studyhttps://practicaldermatology.com/news/novel-ad-drug-shows-promise-in-phase-2-study/2458555/Medimetriks’ MM36 (previously known as OPA-15406) performed well in a Phase 2 trial for the treatment of mild-to-moderate atopic dermatitis, a new study in in Journal of the American Academy of Dermatology shows. The investigational t
- Largest Independent US Psoriasis Registry to Track Safety of Ixekizumab Biologic Treatmenthttps://practicaldermatology.com/news/largest-independent-us-psoriasis-registry-to-track-safety-of-ixekizumab-biologic-treatment/2458583/The Corrona Psoriasis Registry will track the drug safety reporting for ixekizumab, Eli Lilly and Company's biologic medication that was recently approved for the treatment of moderate-to-severe plaque psoriasis. The registry is a joint collaboration between the National Psoriasis Foundation
- Valeant Announces Nominees For Election To Board Of Directorshttps://practicaldermatology.com/news/valeant-announces-nominees-for-election-to-board-of-directors/2458585/Valeant Pharmaceuticals International, Inc. announced the nominees for election to its Board of Directors at the 2016 Annual Meeting of Shareholders on June 14, 2016. As previoulsy announced, Joseph C. Papa has been named Valeant's
- Personalized Medicine In Action: New Biomarker May Pinpoint Aggressive BCChttps://practicaldermatology.com/news/personalized-medicine-in-action-new-biomarker-may-pinpoint-aggressive-bcc/2458598/A biomarker associated with basal cell carcinoma around the eye may help signal which tumors are likely to be aggressive, report researchers from University of Michigan (U-M) at Ann Arbor. The findings, which appear in JAMA Oncology, may help eliminat
- ASA Lauds Three Honorees at Spring Galahttps://practicaldermatology.com/news/asa-lauds-three-honorees-at-spring-gala/2458602/The American Skin Association (ASA) honored Yale Educator Irwin M. Braverman, MD, Melanoma Researcher John M. Kirkwood MD and Nestlé’s SHIELD program at their Spring gala in New
- Phat Lips: Celebrity Lip Envy Driving Explosive Growth in Lip Enhancementhttps://practicaldermatology.com/news/phat-lips-celebrity-lip-envy-driving-explosive-growth-in-lip-enhancement/2458605/Someone gets their lips enhanced every 19 minutes in the US, the American Society of Plastic Surgeons (ASPS) reports. And a new ASPS survey suggests that celebrity lip envy may be driving this trend. The most likeable lips belong to Jennif
- GMC, RCS Raise the Bar for Cosmetic Surgery in the UKhttps://practicaldermatology.com/news/gmc-rcs-raise-the-bar-for-cosmetic-surgery-in-the-uk/2458611/Starting in June 2016, the UK will have new rules and regulations governing the practice of cosmetic surgery and the practices of cosmetic surgeons. The new guidance, issued by the General Medical Council (GMC), aims to reign in cosmetic cowboys in the
- Acella Pharmaceuticals Appoints New CEOhttps://practicaldermatology.com/news/acella-pharmaceuticals-appoints-new-ceo/2458613/Acella Pharmaceuticals, LLC, a specialty pharmaceutical company, announced the appointment of Harold. A Deas, Jr. as Chief Executive Officer. Mr. Deas, who will retain his role as Chief Operating Officer, has been instrumental in helping Acella build a successful portfolio of generic and sp
- FDA Approves Inflectra, a Biosimilar to Remicadehttps://practicaldermatology.com/news/fda-approves-inflectra-a-biosimilar-to-remicade/2458618/And then there were two ... The U.S. Food and Drug Administration approved the biosimilar Inflectra (infliximab-dyyb) for multiple indications. Inflectra is biosimilar to Janssen Biotech, Inc.&rsq